JPWO2021110887A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021110887A5 JPWO2021110887A5 JP2022532833A JP2022532833A JPWO2021110887A5 JP WO2021110887 A5 JPWO2021110887 A5 JP WO2021110887A5 JP 2022532833 A JP2022532833 A JP 2022532833A JP 2022532833 A JP2022532833 A JP 2022532833A JP WO2021110887 A5 JPWO2021110887 A5 JP WO2021110887A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- oxy
- dioxide
- acetic acid
- benzothiazepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 90
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 206010010774 Constipation Diseases 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 206010008635 Cholestasis Diseases 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 230000007870 cholestasis Effects 0.000 claims 9
- 231100000359 cholestasis Toxicity 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 239000003613 bile acid Substances 0.000 claims 8
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 7
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 210000004185 liver Anatomy 0.000 claims 6
- 201000001493 benign recurrent intrahepatic cholestasis Diseases 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- -1 cyano, nitro, amino Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 5
- 208000019423 liver disease Diseases 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 3
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 3
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 3
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 3
- 210000000941 bile Anatomy 0.000 claims 3
- 210000000013 bile duct Anatomy 0.000 claims 3
- 201000005271 biliary atresia Diseases 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 201000001883 cholelithiasis Diseases 0.000 claims 3
- 230000007882 cirrhosis Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 201000011374 Alagille syndrome Diseases 0.000 claims 2
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 2
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims 2
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000029448 Chylomicron retention disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 201000004408 Hypobetalipoproteinemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010023126 Jaundice Diseases 0.000 claims 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000012347 Parenteral nutrition associated liver disease Diseases 0.000 claims 2
- 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 201000008220 erythropoietic protoporphyria Diseases 0.000 claims 2
- 201000000544 familial hypobetalipoproteinemia 1 Diseases 0.000 claims 2
- 230000004129 fatty acid metabolism Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000001130 gallstones Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims 2
- 230000007872 intrahepatic cholestasis Effects 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010067092 AIDS cholangiopathy Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 208000019256 Benign recurrent intrahepatic cholestasis type 2 Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010051341 Bile duct stenosis Diseases 0.000 claims 1
- 206010004637 Bile duct stone Diseases 0.000 claims 1
- 102100028282 Bile salt export pump Human genes 0.000 claims 1
- 208000015163 Biliary Tract disease Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 201000009331 Choledocholithiasis Diseases 0.000 claims 1
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 101000724352 Homo sapiens Bile salt export pump Proteins 0.000 claims 1
- 101000955481 Homo sapiens Phosphatidylcholine translocator ABCB4 Proteins 0.000 claims 1
- 101000671676 Homo sapiens U3 small nucleolar RNA-associated protein 4 homolog Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020915 Hypervitaminosis Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010065973 Iron Overload Diseases 0.000 claims 1
- 101150072399 LSC1 gene Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000015924 Lithiasis Diseases 0.000 claims 1
- 206010025282 Lymphoedema Diseases 0.000 claims 1
- 206010054805 Macroangiopathy Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102100039032 Phosphatidylcholine translocator ABCB4 Human genes 0.000 claims 1
- 206010063985 Phytosterolaemia Diseases 0.000 claims 1
- 235000017284 Pometia pinnata Nutrition 0.000 claims 1
- 240000007653 Pometia tomentosa Species 0.000 claims 1
- 206010057969 Reflux gastritis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000002227 Sitosterolemia Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 102100040072 U3 small nucleolar RNA-associated protein 4 homolog Human genes 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 201000004525 Zellweger Syndrome Diseases 0.000 claims 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000003190 augmentative effect Effects 0.000 claims 1
- 208000021033 autosomal dominant polycystic liver disease Diseases 0.000 claims 1
- 201000001490 benign recurrent intrahepatic cholestasis 1 Diseases 0.000 claims 1
- 201000001488 benign recurrent intrahepatic cholestasis 2 Diseases 0.000 claims 1
- 208000026586 benign recurrent intrahepatic cholestasis type 1 Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000006766 bile reflux Diseases 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000001088 cerebrotendinous xanthomatosis Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 201000008865 drug-induced hepatitis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000014101 glucose homeostasis Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000016245 inborn errors of metabolism Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000015978 inherited metabolic disease Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000002502 lymphedema Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028589 polycystic liver disease Diseases 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 208000000876 primary bile acid malabsorption Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Claims (15)
R1及びR2は各々独立に、C1~4アルキルであり;
R3は独立に、水素、ハロゲン、ヒドロキシ、C1~4アルキル、C1~4ハロアルキル、C1~4アルコキシ、C1~4ハロアルコキシ、シアノ、ニトロ、アミノ、N-(C1~4アルキル)アミノ、N,N-ジ(C1~4アルキル)アミノ、及びN-(アリール-C1~4アルキル)アミノからなる群から選択され;
nは、1、2、又は3の整数であり;
R4は、水素、ハロゲン、ヒドロキシ、シアノ、C1~4アルキル、C3~6シクロアルキル、C1~4アルコキシ、C3~6シクロアルキルオキシ、C1~4アルキルチオ、C3~6シクロアルキルチオ、アミノ、N-(C1~4アルキル)アミノ、及びN,N-ジ(C1~4アルキル)アミノからなる群から選択される)
又は医薬として許容されるその塩であって、
但し、化合物が、
2-((3,3-ジプロピル-7-(メチルチオ)-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-7-(メチルチオ)-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-5-(4-クロロフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-3-エチル-7-(メチルチオ)-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-3-エチル-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-3-エチル-7-メトキシ-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-3-エチル-7-イソプロポキシ-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-7-メトキシ-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((7-ブロモ-3,3-ジブチル-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;及び
2-((7-ブロモ-3-ブチル-3-エチル-5-フェニル-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸
からなる群からの化合物ではないことを条件とする、式(I)の化合物又は医薬として許容されるその塩。 Compound of formula (I)
R 1 and R 2 are each independently C 1-4 alkyl;
R 3 is independently hydrogen, halogen, hydroxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, cyano, nitro, amino, N-(C 1-4 selected from the group consisting of N,N-di(C 1-4 alkyl)amino, and N-(aryl-C 1-4 alkyl)amino;
n is an integer of 1, 2, or 3;
R 4 is hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-4 alkoxy, C 3-6 cycloalkyloxy, C 1-4 alkylthio, C 3-6 cyclo (selected from the group consisting of alkylthio, amino, N-(C 1-4 alkyl)amino, and N,N-di(C 1-4 alkyl)amino)
or a pharmaceutically acceptable salt thereof,
However, if the compound is
2-((3,3-dipropyl-7-(methylthio)-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy) acetic acid;
2-((3,3-dibutyl-7-(methylthio)-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy) acetic acid;
2-((3,3-dibutyl-5-(4-chlorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8- yl)oxy)acetic acid;
2-((3-butyl-3-ethyl-7-(methylthio)-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl) oxy)acetic acid;
2-((3-butyl-3-ethyl-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acetic acid;
2-((3-butyl-3-ethyl-7-methoxy-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy) acetic acid;
2-((3-butyl-3-ethyl-7-isopropoxy-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy ) acetic acid;
2-((3,3-dibutyl-7-methoxy-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acetic acid;
2-((7-bromo-3,3-dibutyl-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acetic acid; as well as
2-((7-bromo-3-butyl-3-ethyl-5-phenyl-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy) A compound of formula (I) or a pharmaceutically acceptable salt thereof, provided that it is not a compound from the group consisting of acetic acid.
2-((3,3-ジブチル-5-(4-メトキシフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((5-(4-ブロモフェニル)-3,3-ジブチル-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-5-(4-ヒドロキシフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-5-(4-シアノフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-7-(メチルチオ)-1,1-ジオキシド-5-(4-(トリフルオロメチル)フェニル)-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-7-(ジメチルアミノ)-3-エチル-1,1-ジオキシド-5-フェニル-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
(S)-2-((3-ブチル-7-(ジメチルアミノ)-3-エチル-1,1-ジオキシド-5-フェニル-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
(R)-2-((3-ブチル-7-(ジメチルアミノ)-3-エチル-1,1-ジオキシド-5-フェニル-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-7-フルオロ-1,1-ジオキシド-5-フェニル-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-7-シアノ-1,1-ジオキシド-5-フェニル-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-3-エチル-7-フルオロ-1,1-ジオキシド-5-フェニル-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3,3-ジブチル-7-クロロ-1,1-ジオキシド-5-フェニル-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-3-エチル-5-(4-フルオロフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
(S)-2-((3-ブチル-3-エチル-5-(4-フルオロフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
(R)-2-((3-ブチル-3-エチル-5-(4-フルオロフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-3-エチル-5-(4-メトキシフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
2-((3-ブチル-3-エチル-5-(4-ヒドロキシフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
(S)-2-((3-ブチル-3-エチル-5-(4-ヒドロキシフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;及び
(R)-2-((3-ブチル-3-エチル-5-(4-ヒドロキシフェニル)-7-(メチルチオ)-1,1-ジオキシド-2,3,4,5-テトラヒドロ-1,5-ベンゾチアゼピン-8-イル)オキシ)酢酸;
からなる群から選択される、請求項1に記載の化合物又は医薬として許容されるその塩。 2-((3,3-dibutyl-7-(dimethylamino)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy ) acetic acid;
2-((3,3-dibutyl-5-(4-methoxyphenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8 -yl)oxy)acetic acid;
2-((5-(4-bromophenyl)-3,3-dibutyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8 -yl)oxy)acetic acid;
2-((3,3-dibutyl-5-(4-hydroxyphenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8 -yl)oxy)acetic acid;
2-((3,3-dibutyl-5-(4-cyanophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8 -yl)oxy)acetic acid;
2-((3,3-dibutyl-7-(methylthio)-1,1-dioxide-5-(4-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydro-1,5-benzo Thiazepin-8-yl)oxy)acetic acid;
2-((3-butyl-7-(dimethylamino)-3-ethyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl )oxy)acetic acid;
(S)-2-((3-butyl-7-(dimethylamino)-3-ethyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine -8-yl)oxy)acetic acid;
(R)-2-((3-Butyl-7-(dimethylamino)-3-ethyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine -8-yl)oxy)acetic acid;
2-((3,3-dibutyl-7-fluoro-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acetic acid;
2-((3,3-dibutyl-7-cyano-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acetic acid;
2-((3-butyl-3-ethyl-7-fluoro-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy) acetic acid;
2-((3,3-dibutyl-7-chloro-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)acetic acid;
2-((3-butyl-3-ethyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine -8-yl)oxy)acetic acid;
(S)-2-((3-butyl-3-ethyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5 -benzothiazepin-8-yl)oxy)acetic acid;
(R)-2-((3-Butyl-3-ethyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5 -benzothiazepin-8-yl)oxy)acetic acid;
2-((3-butyl-3-ethyl-5-(4-methoxyphenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine -8-yl)oxy)acetic acid;
2-((3-butyl-3-ethyl-5-(4-hydroxyphenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine -8-yl)oxy)acetic acid;
(S)-2-((3-butyl-3-ethyl-5-(4-hydroxyphenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5 -benzothiazepin-8-yl)oxy)acetic acid; and
(R)-2-((3-butyl-3-ethyl-5-(4-hydroxyphenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5 -benzothiazepin-8-yl)oxy)acetic acid;
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of.
R1及びR2は各々独立に、C1~4アルキルであり;
R3は独立に、水素、ハロゲン、ヒドロキシ、C1~4アルキル、C1~4ハロアルキル、C1~4アルコキシ、C1~4ハロアルコキシ、シアノ、ニトロ、アミノ、N-(C1~4アルキル)アミノ、N,N-ジ(C1~4アルキル)アミノ、及びN-(アリール-C1~4アルキル)アミノからなる群から選択され;
nは、1、2、又は3の整数であり;
R4は、水素、ハロゲン、ヒドロキシ、シアノ、C1~4アルキル、C3~6シクロアルキル、C1~4アルコキシ、C3~6シクロアルキルオキシ、C1~4アルキルチオ、C3~6シクロアルキルチオ、アミノ、N-(C1~4アルキル)アミノ、及びN,N-ジ(C1~4アルキル)アミノからなる群から選択される)又は医薬として許容されるその塩を含む医薬。 Compound of formula (I)
R 1 and R 2 are each independently C 1-4 alkyl;
R 3 is independently hydrogen, halogen, hydroxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, cyano, nitro, amino, N-(C 1-4 selected from the group consisting of N,N-di(C 1-4 alkyl)amino, and N-(aryl-C 1-4 alkyl)amino;
n is an integer of 1, 2, or 3;
R 4 is hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-4 alkoxy, C 3-6 cycloalkyloxy, C 1-4 alkylthio, C 3-6 cyclo or a pharmaceutically acceptable salt thereof .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201911049985 | 2019-12-04 | ||
IN201911049985 | 2019-12-04 | ||
PCT/EP2020/084571 WO2021110887A1 (en) | 2019-12-04 | 2020-12-04 | Benzothiazepine compounds and their use as bile acid modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023504646A JP2023504646A (en) | 2023-02-06 |
JPWO2021110887A5 true JPWO2021110887A5 (en) | 2023-12-05 |
Family
ID=82196618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022532833A Pending JP2023504646A (en) | 2019-12-04 | 2020-12-04 | Benzothiazepine compounds and their use as bile acid modulators |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4069362A1 (en) |
JP (1) | JP2023504646A (en) |
CN (1) | CN114786773A (en) |
CA (1) | CA3158175A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9800428D0 (en) * | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
EG26979A (en) * | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) * | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
RU2619215C2 (en) * | 2010-11-08 | 2017-05-12 | Альбирео Аб | Pharmaceutical combination comprising ibat-inhibitor and bile acid binder |
-
2020
- 2020-12-04 CN CN202080083824.3A patent/CN114786773A/en active Pending
- 2020-12-04 CA CA3158175A patent/CA3158175A1/en active Pending
- 2020-12-04 JP JP2022532833A patent/JP2023504646A/en active Pending
- 2020-12-04 EP EP20821144.1A patent/EP4069362A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7391048B2 (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
HRP20230039T1 (en) | Benzothiadiazepine compounds and their use as bile acid modulators | |
JPWO2021110883A5 (en) | ||
JPWO2021110885A5 (en) | ||
JPWO2021110884A5 (en) | ||
JPWO2021110886A5 (en) | ||
JP7504110B2 (en) | Benzothiazepine compounds and their use as bile acid modulators - Patents.com | |
US10975046B2 (en) | Crystal modifications of odevixibat | |
JPWO2020161217A5 (en) | ||
JPWO2019234077A5 (en) | ||
JP2023504647A (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
JP2019504898A5 (en) | ||
US20210179572A1 (en) | Benzothiadiazepine compounds and their use as bile acid modulators | |
JP2023504643A (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
JP2023504644A (en) | Benzothiadiazepine compounds and their use as bile acid modulators | |
TW202134218A (en) | Benzothiazepine compounds and their use as bile acid modulators | |
TW202134222A (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
JP2023537285A (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
TW202134223A (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
TW202134221A (en) | Benzothiadiazepine compounds and their use as bile acid modulators | |
TW202134220A (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
JPWO2019245448A5 (en) | ||
JPWO2021110887A5 (en) | ||
RU2021125969A (en) | Benzothiadiazepine Compounds and Their Use as Bile Acid Modulators | |
RU2020142990A (en) | BENZOTIA(DI)AZEPINES AND THEIR USE AS BILE ACID MODULATORS |